Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus Rd in elderly newly diagnosed myeloma
NCT04891809Phase 2Active, not recruiting
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Oct 2021
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoint: Proportion of patients with Minimal Residual Disease negativity at 8 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04891809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891809.